Children's Health Medical Center EOOD
- Address
- lock Available on a paid plan
Children's Health Medical Center EOOD - Psychiatric Research
Children's Health Medical Center EOOD is a clinical research facility conducting advanced studies in mental health and psychiatric disorders. The center specializes in evaluating novel therapeutic interventions for Major Depressive Disorder (MDD) and related psychiatric conditions, with particular expertise in adjunctive treatment approaches that enhance standard care protocols.
- Major Depressive Disorder treatment optimization and adjunctive therapy evaluation
- Depression symptom assessment using validated clinical rating scales including MADRS
- Novel pharmacological interventions for mood disorders in adult populations
The center's research program focuses on assessing both efficacy and safety profiles of investigational compounds, utilizing standardized measurement tools such as the Montgomery-Asberg Depression Rating Scale (MADRS) to quantify therapeutic outcomes. Through rigorous clinical trial methodology, the facility contributes to advancing evidence-based treatment options for patients suffering from depression and other psychiatric conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Acadia Pharmaceuticals Inc.2active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Acadia Pharmaceuticals Inc.2trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Children's Health Medical Center EOOD
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP) | Acadia Pharmaceuticals Inc. | Phase III | Recruiting | May 2026 | — |
IMP list
lock Showing 1 of 8 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Acp-204 Tartrate | 2 | Unknown | 2025-12-04 | 2026-05-17 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.